WORKSHOPWS 04
Combating Antibiotic Resistance
The Role of Market Incentives in Europe for the Development of New Therapies
Date
Sunday, 12th October
Time
14:00-15:30 CEST
12:00-13:30 UTC
Room
Forum 2
About the session
Antimicrobial Resistance (AMR) is one of the biggest threats to global health. In the face of rapidly increasing resistance and a nearly exhausted antibiotic pipeline, it is crucial to establish innovative strategies to promote the development of new antimicrobials.
Within the European Union, solutions urgently need to be found in collaboration with all relevant stakeholders. While market incentives for new antibiotics are still being discussed in the European Union, the United Kingdom has already implemented a model. Targeted incentives are needed to motivate pharmaceutical companies to invest in the research and development of new antimicrobial agents.
Close cooperation between politics, science and industry is essential in order to develop sustainable and forward-looking models. As AMR is a global problem, coordinated action at national, European and international level is essential.
Within the European Union, solutions urgently need to be found in collaboration with all relevant stakeholders. While market incentives for new antibiotics are still being discussed in the European Union, the United Kingdom has already implemented a model. Targeted incentives are needed to motivate pharmaceutical companies to invest in the research and development of new antimicrobial agents.
Close cooperation between politics, science and industry is essential in order to develop sustainable and forward-looking models. As AMR is a global problem, coordinated action at national, European and international level is essential.
Chair(s) / Moderator(s)
Speakers
Takuko Sawada
Shionogi & Co., Ltd.
Director and Vice President of the Board
Japan
Open
Mathias W. Pletz
University Hospital Jena
Institute for Infection Medicine | Director
Germany
Open
Dame Sally Davies
UK Special Envoy on Antimicrobial Resistance (AMR)
United Kingdom
Open
Dagmar Reitenbach
Federal Ministry of Health (BMG)
Medical Devices, Pharmacies, Narcotics | Deputy Director-General
Germany
Open